Group items tagged

The National Center for Complementary and Integrative Health (NCCIH) announces the availability of funds for Administrative Supplements or Urgent Competitive Revisions to promote research on the effects of natural products alone or in combination with other complementary and integrative health approaches on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NCCIH is particularly interested in projects focusing on the therapeutic and/or mechanistic effects on SARS-CoV-2/COVID-19 of natural product-based complementary remedies including, but not limited to: herbal therapies, vitamins, supplements, probiotics, microbial therapies, and Chinese medicine herbal preparations.

The goal of the program is to build a research cohort of one million or more U.S. volunteers who are engaged as partners in a longitudinal, long-term effort to transform the understanding of factors contributing to individual health and disease.

The goal of the program is to build a research cohort of one million or more U.S. volunteers who are engaged as partners in a longitudinal, long-term effort to transform the understanding of factors contributing to individual health and disease.

The Kettering Fund was founded July 1, 1958 by Charles F. Kettering, renowned inventor, businessman and philanthropist. The mission of The Kettering Fund is to support scientific, medical, social and educational studies and research carried on within the State of Ohio. The Fund's Distribution Committees meet biannually (May and November) to determine funding recommendations to the trustees of The Kettering Family Foundation.

 The purpose of this program is to support research activities that expand the knowledge base related to complex products and formulation development, analysis, and manufacturing control to advance risk-based quality assessment of new and generic drug products. We will also consider biological products relevant to CDER (e.g., monoclonal antibodies and therapeutic proteins) for this announcement.       

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/) ("Client"), seeks a drug modality for novel anti-cancer drugs that target immunosuppressive cells and interfere with immune functions, or an evaluation system for creating a drug modality. In recent years, the emergence of immune checkpoint inhibitors has been gradually revealing that the local immunosuppressive environment in tumor affects cancer treatment. This attracts interest in the development of novel antitumor drugs for improving the immune state of the tumor microenvironment. In particular, we look for compounds that target host cells contributing to the formation of the immunosuppressive environment and interfering with these functions.

This opportunity supports research opportunities that will advance our understanding of, and the implementation of, the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use.

PSC Partners Seeking a Cure is a nonprofit foundation whose mission is to provide education and support to patients with primary sclerosing cholangitis, their families, and their caregivers and to raise funds for research on the causes, treatments, and cures for PSC, an autoimmune disease that causes the bile ducts inside and outside the liver to become scarred, narrowed, and eventually blocked. The foundation offers grants of up to $60,000 over two years in support of projects that address a novel, basic, or clinical research question related to PSC and closely allied diseases (such as inflammatory bowel diseases, ulcerative colitis, or Crohn's disease) as they relate to PSC. Preference will be given to projects that have the potential to discover a cure for the disease and/or that identify novel therapies which may significantly delay time to liver transplantation, prevent disease recurrence following liver transplantation, and/or improve the quality of life of those with PSC.

Dr. Chockalingam Sivakumar and his study team at Global Mantra Innovation are seeking interested collaborators to provide SME support and site identification for a Disease Management Analytics platform on a retrospective observational study about Type-2 Diabetes Mellitus.

This funding opportunity announcement (FOA) seeks US domestic research projects that address how food insecurity effects HIV comorbidities, coinfections, and complications (CCCs) within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The approaches may address the pathways linking food insecurity and the development or exacerbation of CCCs; or they may evaluate the mechanisms whereby interventions that alleviate food insecurity improve CCCs. These mechanisms could be related to nutritional inadequacies or patient health-related behaviors.

This funding opportunity announcement (FOA) seeks US domestic research projects that address how food insecurity effects   HIV comorbidities, coinfections, and complications (CCCs) within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The approaches may address the pathways linking food insecurity and the development or exacerbation of CCCs; or they may evaluate the mechanisms whereby interventions that alleviate food insecurity improve CCCs. These mechanisms could be related to nutritional inadequacies or patient health-related behaviors.

The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.

The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.

Grants are targeted primarily to new or junior investigators within seven years of attaining a terminal degree (e.g., PhD, EdD), and are expected to provide seed-money support after which further funding will be sought from other sources.

This is an invitation for collaborative proposals which focus on addressing the challenges Primary Care Providers experience in serving Adults with Intellectual and Developmental Disabilities during pandemic and/or emergency situations. Proposals should use one of the following approaches: Educational materials: Develop additional educational resources related to pandemic and/or emergency response for Primary Care Providers who serve adults with I/DD Implementation: Supports implementation of models, i.e. projects that support community-based PCPs in providing care to adults with I/DD during pandemic and/or emergency situations Research: Supports regional or national research related to Primary Care Providers who serve adults with I/DD role during pandemic and emergency situations A secondary goal of this RFP is to foster new partnerships or significantly enhance existing partnerships between disability organizations, advocates, community organizations, and healthcare providers. Grants of up to $50,000 (each) for a 1-year period will be awarded.